drugset / Trial / NCT00309478
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Phase 3
Completed
1099 enrolled
Austrian Breast & Colorectal Cancer Study Group
AstraZeneca · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Primarily, this clinical investigation compared the efficacy of cyclophosphamide + methotrexate + fluorouracil chemotherapy vs. goserelin + tamoxifen treatment in terms of prognosis (disease-free survival, overall survival) in premenopausal patients with potentially curative, operated hormone receptor-positive breast cancer.
Timeline
- Start
- 1990-12
- Primary completion
- 2004-06
- Completion
- 2004-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Subject | Goserelin | Other / unclassified | 3.6 mg | — |
| Subject | Methotrexate | Small molecule | 40 mg/m2 | — |
| Subject | Tamoxifen | Small molecule | 20 mg | — |
| Subject | fluorouracil | Small molecule | 600 mg/m2 | — |